Homeopathic medicines in menopausal syndrome

Double-blind, randomized, placebo-controlled, feasibility trial of individualized homeopathic medicines in menopausal syndrome

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/03/031718

Enrollment

Registered

2021-03-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N951- Menopausal and female climactericstates

Interventions

Intervention1: Individualized homeopathic medicines: It is planned as administering indicated homeopathic remedies in centesimal potencies, as decided appropriate to the case or condition. In centesim

dosage and repetition depending upon the individual requirement of the cases. All medicines will be procured from a Good Manufacturing Practice (GMP)-certified firm. Route of administration of medicin

e.g. soyabean, nuts and seeds (flaxseeds, sunflower seeds, sesame seeds, almonds, walnuts), fruits (apples, carrots, pomegranates, strawberries, cranberries, grapes), grains (oats, barley, wheat) and

dosage and repetition depending upon the individual requirement of the cases. All sundry items will be procured from a Good Manufacturing Practice (GMP)-certified firm. Route of administration: Oral.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Cases suffering from menopausal syndrome for at least 3 months (ICD-10-CM diagnosis code N95.1) 2. Age 40-55 years 3. Patients who are literate and capable of filling the questionnaire and providing written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients who had an artificial menopause and are on HRT 2. Patients having history of breast or reproductive organ cancer 3. Patients with psychiatric diseases 4. Cases suffering from uncontrolled systemic illness or life-threatening infections 5. Cases already undergoing homeopathic treatment for any chronic purpose 6. Substance abuse and/or dependence

Design outcomes

Primary

Measure	Time frame
Menopause Rating Scale (MRS)Timepoint: At baseline and after 2 months	—

Secondary

Measure	Time frame
Greene Climacteric Scale (GCS)Timepoint: At baseline and after 2 months;Utian Quality of Life (UQoL) questionnaire scoresTimepoint: At baseline and after 2 months	—

Countries

India

Contacts

Public ContactKhalida Hassan

D. N. De Homoeopathic Medical College and Hospital

shyamalmukhergee@gmail.com9831113383

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026